Australia has become the first country outside of the United States to approve the use of the drug pegcetacoplan (SYFOVRE) to slow down the progression of geographic atrophy.

Astellas Pharma seeks Japanese conditional approval of avacincaptad pegol intravitreal solution to treat geographic atrophy: Tokyo Thursday, February 6, 2025, 09:00 Hrs [IST] Aste ...

Ministry of Health, Labour and Welfare to evaluate ACP as potential first and only treatment for patients with geographic atrophy (GA) secondary ...

In this CE activity, experts in the field will assess how advances in imaging and new therapies for the management of geographic atrophy ... for the treatment and management of retinal vein ...

SBL03 was formulated as an ophthalmic gel for non-invasive topical delivery. Its unique ability to infiltrate eye tissues effectively and protect ret ...

Discover the importance of vision, genetic eye disorders, and RNA-based therapies for precision treatment in India and ...

The best treatment begins with just focusing on slowing down progressive renal failure, and that means using ACE inhibitors or ARBs combined with an SGLT2. If you're talking about stage three and ...

and treatment primarily focuses on managing its symptoms, addressing functional impairments, and providing cosmetic reconstruction to improve quality of life. Parry-Romberg Syndrome (PRS) is primarily ...

Australia's Therapeutic Goods Administration has approved the use of a new and first treatment for geographic atrophy - a disease which causes severe, progressive central vision loss and is a leading ...

This marks the first approved treatment for ... It is a progressive and irreversible disease caused by the growth of lesions, which destroy the retinal cells responsible for vision.

WALTHAM, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE® (pegcetacoplan) for the every-other-month ...